Skip to main content

Table 2 Patient demographics

From: The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial

Patient characteristic

Total

Fluoxetine

Placebo

P-value*

 

N = 34 (100%)

N = 18 (53%)

N = 16 (47%)

 

Ethnicity, n (%)

   

.75

White

25 (73%)

14 (78%)

11 (19%)

 

African American

6 (18%)

3 (17%)

3 (69%)

 

Other

3 (9%)

1 (5%)

2 (12%)

 

Age (years), mean ± SD

16.46 ± 1.08

16.55 ± 1.11

16.35 ± 1.08

.61

Gender, n (%)

   

.18

Female

5 (15%)

4 (22%)

1 (6%)

 

Male

29 (85%)

14 (78%)

15 (94%)

 

Current Depressive Disorder

MDDa

29 (85.3%)

15 (83.3%)

14 (87.5%)

1.0

Other Depressive Disorderb

5 (14.7%)

3 (16.7%)

2 (12.5%)

.56

Age at onset of depression, mean ± SD

11.41 ± 2.5

11.9 ± 2.7

10.8 ± 2.1

.19

Length of depression, mean ± SD (weeks)

213.1 ± 153.6

185.0 ± 168.3

244.7 ± 133.4

.26

Current comorbid condition, n (%)

ADHDc

11 (32.4%)

6 (33%)

5 (31.3%)

1.0

Post Traumatic Stress Disorder

2 (5.9%)

1 (5.6%)

1 (6.3%)

1.0

Conduct Disorder

2 (5.9%)

0 (0%)

2 (12.5%)

.21

Current SUD d,e

Alcohol

13 (38.2%)

7 (38.9%)

6 (37.5)

1.0

Alcohol Abuse

10 (29.4%)

5 (27.8%)

5 (31.25%)

1.0

Alcohol Dependence

3 (8.8%)

2 (11.1%)

1 (6.25%)

 

Cannabis

30 (88.2%)

15 (83.3%)

15 (93.8%)

.60

Cannabis Abuse

16 (47%)

9 (50.0%)

7 (43.8%)

.72

Cannabis Dependence

14 (41.2%)

6 (33.3%)

8 (50.0%)

 

Polysubstance

1 (2.9%)

0 (0%)

1 (6.3%)

.47

Age at onset of SUD e , mean ± SD

13.7 ± 1.2

13.8 ± 1.3

13.7 ± 1.3

.86

Length of SUD, mean ± SD (weeks)

117.4 ± 68.7

116.0 ± 72.4

118.9 ± 66.8

.91

  1. aMajor Depressive Disorder; 2 patients with MDD had a comorbid Dysthymic disorder diagnosis
  2. b4 patients were diagnosed with Dysthymic Disorder, 3 patients had Depression Not Otherwise Specified
  3. cAttention Deficit/Hyperactivity Disorder
  4. dSubstance Use Disorder
  5. e10 patients had more than one substance use disorder
  6. *Fisher's exact test analyses were used to compare percentages; generalized linear model (GLM) procedures were used for comparisons of continuous variables between treatment groups